🏥  $ELV: $277.09, -$25.36 (-8.38%) 💸🧗♀️
📅 As of Jul-18-2025, 4:10 PM ET

🎯 Trigger Alert:
On July 18, Elevance Health’s CEO, Gail Boudreaux, just bought 8,500 shares at $286.94, dropping a cool $2.4 million into $ELV stock. That’s a +6% increase in her holdings, totaling over 151,000 shares now. 👀
Insider conviction? Big time. 💪

🧠 Who is Gail Boudreaux?

She’s no rookie.
✔️ CEO since 2017
✔️ Former CEO of UnitedHealthcare
✔️ Senior exec roles at Aetna and HCSC
✔️ Regular on Fortune’s Most Powerful Women list
✔️ Still buying shares as the stock dives 🚨

So… why the plunge? 🤔

📉 What Just Happened?

The stock dropped nearly 10% after Q2 earnings disappointed:

• Operating revenue: $49.4B (+14.3% YoY)

• Adjusted EPS: $8.84

• BUT FY25 guidance was slashed:
  📉 From $34.50-ish ➡️ $30.00

Elevated medical costs in Medicaid and ACA plans are to blame. And ELV’s not alone:
🩺 Centene ($CNC) = down 75% from peak
🩺 Molina ($MOH) = down 10% yesterday
🩺 Even UnitedHealth ($UNH) = limping

The whole managed care sector is getting pummeled.

💸 Institutions Are Still In

📦 2,230 Institutions own 93.23% of the float (!)
Talk about conviction 💥

Top Holders:

🏥 What Elevance Actually Does

It’s not just insurance:
✔️ Health Plans (Medicare, Medicaid, BlueCard, etc.)
✔️ Pharmacy Services (CarelonRx, specialty meds)
✔️ Clinical & Behavioral Health
✔️ Home health, palliative care, virtual care
✔️ Data analytics, subrogation, IT services

Formerly known as Anthem Inc., the company rebranded as Elevance in 2022—because, well, you gotta elevate when healthcare costs are out of control. 🚁

📊 Key Takeaways from Q2 Earnings

• ✅ Sales keep rising:
  $171B (2023) → $177B (2024) → $183B (TTM)

• ⚠️ Profitability under attack:
  Benefit Expense Ratio = 88.9% (+260bps YoY)
  That means more $$ spent on care, squeezing the bottom line.

• 💵 Shareholder love continues:
  🔁 $379M in share buybacks
  💰 $1.71 dividend per share
  🪙 $2B returned YTD

• 🧮 Cash flow remains strong:
  $3.1B operating cash flow, up $0.6B YoY
  $2.2B in cash/investments on hand

👉 Want the full picture? Dive into Elevance Health's financials here.

💰 But the Stock Got Slammed

From ATH of $567 in Sep 2024
Now? $277 😬
That’s a 50% crash in less than a year.
But maybe… that’s the opportunity?

🏷️ Value Play in the Making?

Valuation Metrics:

The stock is now in bargain territory—but you’ll need patience, not adrenaline.

📈 Our Take

There’s still plenty to like:

• Stable revenues

• Scale and moat in health services

• Cash-rich and shareholder-friendly

• Smart, seasoned CEO buying big

• Strong institutional backing

• A market that might be over-punishing it

⚠️ Risks

• Rising healthcare costs won’t vanish overnight

• Medicaid/Affordable Care Act pressures and regulatory risks are real—even if the name ‘Affordable’ tries to reassure us otherwise

• Sector sentiment remains negative

• Short-term pain could linger

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

🧭 Bottom Line

This is not a get-rich-quick story.
But if you’ve got a long enough runway—and a stomach for turbulence—Elevance might just rise again.

🎵 The CEO is singing an anthem. Are you listening?

🚨 Disclaimer:

Do your own research. 🎤💼🧠

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny